Institut du Cancer de Montpellier (ICM)

The Institut du Cancer de Montpellier is one of the 18 French Centres de Lutte Contre le Cancer (CLCC) that make up the Unicancer network. It combines a dedicated cancer hospital with the Montpellier Cancer Research Institute (IRCM, Inserm and University of Montpellier) and an early-phase trials unit, and is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre. Research strengths include radiotherapy and radiobiology, biomarkers and circulating tumour DNA, colorectal and breast cancer, and supportive care. The institute is part of the Montpellier SIRIC and hosts Unicancer national trials.

Location

Montpellier, FR

Type

cancer center

Website

www.icm.unicancer.fr

Newsweek 2026 oncology rank

Not in top 300 listing used

OnCo score

#518 · 6 points (0 Newsweek + 0 NCI + 6 from 3 linked objects) · ranking

Research output

From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.

Matched to Institut Regional du Cancer de Montpellier, including child institutions. 434 works · 7,776 citations · 66% open access · 16% clinical trials · 1% reviews.

Oncology works per year

812022

922023

1002024

932025

682026

Most works

Most cited

Work	Journal	Year	Citations
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer 10.1056/nejmoa2203690 · open access	New England Journal of Medicine	2022	2,666
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial 10.1016/s0140-6736(22)02420-5 · open access	The Lancet	2022	681
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 10.1016/j.annonc.2022.09.159 · open access	Annals of Oncology	2022	469
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer 10.1001/jamaoncol.2022.3829 · open access	JAMA Oncology	2022	347
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer 10.1016/j.annonc.2023.05.008 · open access	Annals of Oncology	2023	310
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial 10.1016/j.annonc.2024.06.019 · open access	Annals of Oncology	2024	220
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. conference abstract · 10.1200/jco.2023.41.17_suppl.lba3504	Journal of Clinical Oncology	2023	110
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). conference abstract · 10.1200/jco.2024.42.17_suppl.lba1000	Journal of Clinical Oncology	2024	106
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort 10.1016/j.ejca.2023.04.012 · open access	European Journal of Cancer	2023	95
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort 10.1016/j.jhepr.2023.100719 · open access	JHEP Reports	2023	90
The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases 10.7150/thno.72853 · open access	Theranostics	2022	74
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial 10.1136/ijgc-2023-004995 · open access	International Journal of Gynecological Cancer	2023	64
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial 10.1002/cam4.7235 · open access	Cancer Medicine	2024	60
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer 10.1038/s41416-024-02766-9 · open access	British Journal of Cancer	2024	55
Cancer-associated fibroblast spatial heterogeneity and EMILIN1 expression in the tumor microenvironment modulate TGF-β activity and CD8 + T-cell infiltration in breast cancer 10.7150/thno.90627 · open access	Theranostics	2024	52

Programmes

3top

Radiotherapy and radiobiology
Early-phase trials
ctDNA and biomarkers

People

1top

Marc Ychou

Directeur Général (Director General), Institut du Cancer de Montpellier

Medical oncologyDigestive oncologyCancer centre management

Medical oncologist who is Director General of the Institut du Cancer de Montpellier, the reference cancer centre for eastern Occitanie founded in 1923.

Connected

4top

Institution
Centre François Baclesse
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Jean Perrin
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Henri Becquerel
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Eugène Marquis
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Institut de Cancérologie de l'Ouest (ICO)
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Hospital Universitario Fundación Jiménez Díaz
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
University Medical Center Groningen Comprehensive Cancer Center
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
ASST Spedali Civili di Brescia
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Institut du Cancer de Montpellier (ICM)

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Institut du Cancer de Montpellier (ICM)

Overview

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Institut du Cancer de Montpellier (ICM)

Overview

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people